Clinical

Dataset Information

0

Sotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation


ABSTRACT: The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated colorectal cancer (CRC) receiving sotorasib 240 mg once daily (QD) and panitumumab vs investigator’s choice (trifluridine and tipiracil, or regorafenib), and sotorasib 960 mg QD and panitumumab vs investigator’s choice (trifluridine and tipiracil, or regorafenib).

DISEASE(S): Colorectal Cancer (crc),Sarcoma,Colorectal Neoplasms

PROVIDER: 2401536 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2541579 | ecrin-mdr-crc
| 2386782 | ecrin-mdr-crc
2015-10-08 | GSE69680 | GEO
2023-11-22 | GSE243151 | GEO
| 2586699 | ecrin-mdr-crc
| 2344028 | ecrin-mdr-crc
2021-01-27 | GSE148947 | GEO
| 2400785 | ecrin-mdr-crc
| 2403437 | ecrin-mdr-crc
2023-03-31 | GSE226221 | GEO